Regnology Launches RRH Ascend, Leveraging Straight-Through Reporting to Modernize Financial Regulation
19.11.2025 08:00:00 CET | Business Wire | Press Release
Regnology, a leading software provider with a focus on regulatory reporting and supervisory technology solutions, today announced the launch of RRH Ascend, the next generation of its Regnology Reporting Hub (RRH) solution for banking and transaction reporting. The unveiling will take place at the 32nd annual RegTech Convention, the largest global conference on financial regulation, which brings together more than 2,000 participants across nine cities in a hybrid format.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118412298/en/
RRH Ascend marks a major step towardStraight-Through Reporting (STR)—a new standard designed to eliminate friction in regulatory processes through end-to-end automation, seamless data integration, and intelligent oversight. Modeled on the principles of Straight-Through Processing (STP) in capital markets, STR enables continuous, data-driven exchanges between institutions and regulators, reducing manual intervention and improving efficiency.
With RRH Ascend, Regnology brings this vision to life —accelerating the industry toward greater transparency, efficiency, and trust through four pillars of excellence: data governance, regulatory insight, automation intelligence, and collaboration. Powered by Regnology’s cloud-native platform, the solution leverages the proven foundation of RRH to accelerate transformation with a seamless transition and next-generation capabilities.
Financial institutions can harmonize data architectures, automate regulatory workflows, and deliver regulator-ready outputs in real time—streamlining bank regulation, transaction reporting, data governance, and exception monitoring. Purpose-built for the demands of modern compliance and designed to evolve with advanced AI capabilities, RRH Ascend strengthens the accuracy, speed, and completeness of regulatory submissions across jurisdictions.
Linda Middleditch, Chief Product Officer at Regnology, said: “For too long, financial regulatory reporting has been seen as a laggard – complex, fragmented, and reactive. RRH Ascend represents a turning point, providing institutions with the clarity and control needed to adopt a fully connected, intelligence-led model. This launch accelerates the industry’s shift toward STR and a new era of regulatory intelligence.”
Early adopters of RRH Ascend are now onboarding, with full deployment expected in 2026.
About Regnology
Regnology is a leading technology firm on a mission to enhance efficiency, transparency and stability in the financial markets. Regnology has a focus on regulatory reporting with thousands of financial institutions and corporates of all sizes, and close to 100 regulators and tax authorities as clients. Regnology connects regulators and regulated financial institutions across the world through purpose-built solutions and common standards, bringing greater data quality and cost savings to all. With over 1,200 employees in 25 countries and a fast, flexible and future-proof platform, clients can quickly implement and derive value from Regnology’s solutions and rely on us to easily keep pace with ongoing regulatory changes.
Regnology was formed in 2021 when BearingPoint RegTech, a former business unit of BearingPoint Group, joined forces with Vizor Software, a global leader in regulatory and supervisory technology.
For more information about Regnology, connect with us on LinkedIn and X.
Visit our website: www.regnology.net.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118412298/en/
Contacts
Press Contact
Mireille Adebiyi – Chief Marketing Officer
Email: mireille.adebiyi@regnology.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom